Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion

Wu,Xiao-Jun; Gao,Feng; Liu,Xu; Zhao,Qing

doi:10.3892/etm.2016.3681

Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion

Authors:
- Xiao-Jun Wu
- Feng Gao
- Xu Liu
- Qing Zhao
View Affiliations

Affiliations: Department of Ophthalmology, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: September 7, 2016 https://doi.org/10.3892/etm.2016.3681
Pages: 2617-2621
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to observe the clinical efficacy and safety of recombinant tissue plasminogen activator (rt-PA) combined with compound anisodine in treating central retinal artery occlusion (CRAO). Forty-eight patients diagnosed with CRAO were randomly divided into a treatment group (24 cases) and a control group (24 cases). For the control group, nitroglycerin, 654-2, methazolamide, puerarin and compound anisodine were used for the treatment, along with oxygen, massage and other conventional treatments. Besides conventional therapy, the treatment group was also given intravenous rt-PA thrombolysis. Visual acuity, fundus oculi, visual field changes were taken as indicators for efficacy evaluation. It was found that the total effective rate of the control group was 70.83%, while that for the treatment group was 91.67%, and the comparative difference between the two groups was of statistical significance (p<0.05). The visual field defect of the control group after treatment was approximately 74.26±12.91%, and the visual field defect of the treatment group after treatment approximately 35.08±16.33%; thus, the comparative difference was statistically significant (p<0.01). The comparative difference of the original contents of fibrous protein in blood in the treatment group before and after treatment was statistically significant (p<0.01). In conclusion, the result show that intravenous thrombolysis with rt-PA combined with compound anisodine is safe and effective in treating CRAO, which can significantly improve the prognosis of patients.

View Figures

View References

1	Yen JC, Lin HL, Hsu CA, Li YC and Hsu MH: Atrial fibrillation and coronary artery disease as risk factors of retinal artery occlusion: a nationwide population-based study. BioMed Res Int. 2015:3746162015. View Article : Google Scholar : PubMed/NCBI
2	Antoun JS, Slim EA, Hemade AI, Awada S, Fakhoury HW and Cherfan CG: Idiopathic central retinal artery occlusion in an eight-year-old girl. J Fr Ophtalmol. 39:e1–e3. 2016. View Article : Google Scholar : PubMed/NCBI
3	Naff NJ, Carhuapoma JR, Williams MA, Bhardwaj A, Ulatowski JA, Bederson J, Bullock R, Schmutzhard E, Pfausler B, Keyl PM, Tuhrim S and Hanley DF: Treatment of intraventricular hemorrhage with urokinase : Effects on 30-Day survival. Stroke. 31:841–847. 2000. View Article : Google Scholar : PubMed/NCBI
4	Wardlaw JM, Murray V, Berge E, Del ZG, Sandercock P, Lindley RL and Cohen G: Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet. 379:2364–2372. 2012. View Article : Google Scholar : PubMed/NCBI
5	Schmidt DP, Schulte-Mönting J and Schumacher M: Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. AJNR Am J Neuroradiol. 23:1301–1307. 2002.PubMed/NCBI
6	Hayreh SS and Zimmerman MB: Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 140:376–391. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wardlaw JM, Murray V, Berge E and Del Zoppo GJ: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 7:CD0002132009.
8	Yokoyama S, Manabe Y, Fujii D, Ikeda-Sakai Y, Narai H, Omori N and Abe K: Intravenous tissue plasminogen activator therapy for an acute ischemic stroke patient with later diagnosed unilateral moyamoya syndrome. J Stroke Cerebrovasc Dis. 22:1190–1192. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhou ZG, Wang RL and Yu KL: Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication. Chin Med J (Engl). 125:2775–2776. 2012.PubMed/NCBI
10	Hattenbach LO, Kuhli-Hattenbach C, Scharrer I and Baatz H: Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol. 146:700–706. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chen CS, Lee AW, Campbell B, Lee T, Paine M, Fraser C, Grigg J and Markus R: Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial. Stroke. 42:2229–2234. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kattah JC, Wang DZ and Reddy C: Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion. Arch Ophthalmol. 120:1234–1236. 2002.PubMed/NCBI
13	Nowak RJ, Amin H, Robeson K and Schindler JL: Acute central retinal artery occlusion treated with intravenous recombinant tissue plasminogen activator. J Stroke Cerebrovasc Dis. 21:913.e5–913.e8. 2012. View Article : Google Scholar
14	Hazin R, Dixon JA and Bhatti MT: Thrombolytic therapy in central retinal artery occlusion: cutting edge therapy, standard of care therapy, or impractical therapy? Curr Opin Ophthalmol. 20:210–218. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mach R and Procházka J: Thrombolysis in central retinal artery occlusion using alteplase. Cesk Slov Oftalmol. 64:245–248. 2008.(In Czech). PubMed/NCBI
16	Ma J, Yang X and Li Z: Research progess on introducing thrombolytic therapy into treating retinal central artery occlusion. Int Rev Opthalmology. 25:1–4. 2001.
17	Sugiura S, Iwaisako K, Toyota S and Takimoto H: Simultaneous treatment with intravenous recombinant tissue plasminogen activator and endovascular therapy for acute ischemic stroke within 3 hours of onset. AJNR Am J Neuroradiol. 29:1061–1066. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wi JM and Chi M: Rhabdomyolysis presenting as orbital apex syndrome. J Craniofac Surg. 27:e48–e50. 2016. View Article : Google Scholar : PubMed/NCBI
19	Rodríguez Villa S, Méndez R Salazar, Martín M Cubillas and Cuesta García M: Central retinal artery occlusion after phacoemulsification under peribulbar anaesthesia: pathogenic hypothesis. Arch Soc Esp Oftalmol. 91:40–43. 2016.(In Spanish). PubMed/NCBI
20	Chavala SH, Williamson JF and Postel EA: Embolic central retinal artery occlusion after subcutaneous auricular steroid injection. Lancet. Nov 26–2015.(Epub ahead of print).
21	Ahn SJ, Park KH, Ryoo NK, Hong JH, Jung C, Yoon CH, Han MK and Woo SJ: No-reflow phenomenon in central retinal artery occlusion: incidence, risk factors, and clinical implications. PLoS One. 10:e01428522015. View Article : Google Scholar : PubMed/NCBI
22	Rajabi MT, Naderan M, Mohammadi SZ and Rajabi MB: Central retinal artery occlusion following orbital tumor resection: is rapid intervention effective? Indian J Ophthalmol. 63:678–680. 2015. View Article : Google Scholar : PubMed/NCBI
23	Lu CW, Wang J, Zhou DD, Hao JL, Liang LL, Li XH and Hui P: Central retinal artery occlusion associated with persistent truncus arteriosus and single atrium: a case report. BMC Ophthalmol. 15:1372015. View Article : Google Scholar : PubMed/NCBI
24	Miller NR: Should patients with acute central retinal artery occlusion be treated with intra-arterial t-PA?: Comment. J Neuroophthalmol. 35:4442015. View Article : Google Scholar : PubMed/NCBI
25	Beck KD and Hernandez L: Central retinal artery occlusion in a 21-year-old boxer. Ophthalmology. 122:15682015. View Article : Google Scholar : PubMed/NCBI
26	de Castro-Abeger AH, de Carlo TE, Duker JS and Baumal CR: Optical coherence tomography angiography compared to fluorescein angiography in branch retinal artery occlusion. Ophthalmic Surg Lasers Imaging Retina. 46:1052–1054. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sharma M, Prashar A, Tuli R, Sharma RK and Mahajan VK: Atypical central retinal artery occlusion: an uncommon cause of retinopathy and visual loss in dermatomyositis. Int J Rheum Dis. Sep 25–2015.(Epub ahead of print). View Article : Google Scholar
28	Liu WD, Chen LL, Shen CY and Jiang LB: Neuroprotective effect of compound anisodine in a mouse model with chronic ocular hypertension. Chin Med J (Engl). 128:2652–2657. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhu Y, Song C and Wang S: [The changes of hemodynamics in ocular trauma and treatment with compound anisodine]. Zhonghua Yan Ke Za Zhi. 32:110–113. 1996.PubMed/NCBI